MEI Pharma, Inc. (MEIP) Option Bulls Jump In as Stock Plunges

MEI Pharma Inc (MEIP) calls are hot, despite the drugmaker's significant plunge

Mar 23, 2015 at 11:13 AM
facebook twitter linkedin


MEI Pharma Inc (NASDAQ:MEIP) is getting demolished this morning, after the firm unveiled disappointing data on its cancer drug. The stock -- now relegated to the short-sale restricted list -- has lost more than two-thirds of its value to trade at $1.99, and earlier touched a six-year low of $1.87. Nevertheless, it looks like option traders aren't giving up on MEIP.

Overall options volume is running at four times the average intraday clip, though calls have outnumbered puts so far. Digging deeper, possible buy-to-open activity has been detected at the April 2.50, 5, and 7.50 calls, with the buyers expecting MEIP to muscle back atop the respective strikes by the close on Friday, April 17, when the newly front-month contracts expire.

Prior to today, MEIP was making strides on the charts, and had outpaced the broader S&P 500 Index (SPX) by 66 percentage points over the past two months. Nevertheless, short-term puts were more popular than usual, as the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.86 stands higher than 82% of all other readings from the past year. In the same skeptical vein, short interest jumped 30% during the last reporting period (but still represents a scant 4.3% of MEIP's total float).

Analysts, on the other hand, were decidedly bullish on MEI Pharma Inc (NASDAQ:MEIP). In fact, all eight covering brokerage firms harbored "strong buy" opinions. Today, however, Roth Capital slapped MEIP with a downgrade to "neutral" from "buy," and took an axe to its price target, revising it to $2.50 from $14.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners